Related Experiment Video

Updated: May 21, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a

Manel Pladevall-Vila1,2, Ryan Ziemiecki3, Catherine B Johannes4

  • 1RTI Health Solutions, Barcelona, Spain.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|March 19, 2025
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use increased steadily in patients with type 2 diabetes and chronic kidney disease. Treatment persistence was high and use was independent of CKD severity.

Area of Science:

  • Nephrology
  • Endocrinology
  • Real-world evidence studies

Background:

  • Emerging novel therapies aim to prevent chronic kidney disease (CKD) progression in type 2 diabetes (T2D) patients.
  • The FOUNTAIN platform (NCT05526157) facilitated a real-world study on glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.
  • Characterized adult cohorts with CKD and T2D initiating GLP-1 RA therapy across Europe, Japan, and the US (2012-2021).

Purpose of the Study:

  • To characterize real-world cohorts of adults with CKD and T2D initiating GLP-1 RA therapy.
  • To analyze baseline characteristics and treatment patterns of GLP-1 RA initiators.
  • To assess the association of GLP-1 RA use with CKD severity.

Main Methods:

  • Multinational, multicohort study using five data sources (Denmark, Netherlands, Spain, Japan, US).
  • Included patients with T2D and CKD initiating GLP-1 RA between 2012-2021.
  • Analyzed baseline demographics, lifestyle, clinical characteristics, and treatment patterns.

Main Results:

  • Over 90,000 GLP-1 RA initiators across five cohorts.
  • Mean age ranged from 66.1 to 67.9 years; male proportion varied between 46.6% and 59.6%.
  • GLP-1 RA initiations steadily increased from 2012 to 2019; treatment persistence at 1 year was high (52-78%). GLP-1 RA use was independent of CKD severity.

Conclusions:

  • GLP-1 RA use significantly increased in patients with T2D and CKD from 2012-2021.
  • High treatment persistence was observed across multinational cohorts.
  • GLP-1 RA initiation and use were not dependent on the severity of chronic kidney disease.
Keywords:
ChronicChronic kidney diseaseDiabetes mellitusDrug utilizationFOUNTAIN platformGlucagon-like peptide-1 receptor agonistsRenal insufficiencyType 2

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.6K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

155

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
216
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148